396 related articles for article (PubMed ID: 8878606)
1. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
[TBL] [Abstract][Full Text] [Related]
2. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
[TBL] [Abstract][Full Text] [Related]
3. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
4. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer.
Rolston KV; Nguyen H; Messer M
Antimicrob Agents Chemother; 1990 Nov; 34(11):2137-41. PubMed ID: 2149921
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
Bezian MC; Ribou G; Masquelier B
Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.
Malathum K; Coque TM; Singh KV; Murray BE
Antimicrob Agents Chemother; 1999 Apr; 43(4):930-6. PubMed ID: 10103202
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of LY264826 compared to other glycopeptides and daptomycin.
Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(2):181-4. PubMed ID: 1651826
[TBL] [Abstract][Full Text] [Related]
10. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
[TBL] [Abstract][Full Text] [Related]
11. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.
Malabarba A; Ciabatti R; Scotti R; Goldstein BP; Ferrari P; Kurz M; Andreini BP; Denaro M
J Antibiot (Tokyo); 1995 Aug; 48(8):869-83. PubMed ID: 7592033
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
[TBL] [Abstract][Full Text] [Related]
13. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
al-Nawas B; Shah PM
Infection; 1998; 26(3):165-7. PubMed ID: 9646108
[TBL] [Abstract][Full Text] [Related]
14. Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci.
Rodriguez MJ; Snyder NJ; Zweifel MJ; Wilkie SC; Stack DR; Cooper RD; Nicas TI; Mullen DL; Butler TF; Thompson RC
J Antibiot (Tokyo); 1998 Jun; 51(6):560-9. PubMed ID: 9711219
[TBL] [Abstract][Full Text] [Related]
15. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the new glycopeptide decaplanin.
Neu HC; Chin NX; Niu WW
Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
[TBL] [Abstract][Full Text] [Related]
17. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
18. Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.
Jones ME; Gesu G; Ortisi G; Sahm DF; Critchley IA; Goglio A;
Clin Microbiol Infect; 2002 Feb; 8(2):101-11. PubMed ID: 11952723
[TBL] [Abstract][Full Text] [Related]
19. Glycopeptide carboxamides active against vancomycin-resistant enterococci.
Zweifel MJ; Snyder NJ; Cooper RD; Nicas TI; Mullen DL; Butler TF; Rodriguez MJ
J Antibiot (Tokyo); 2003 Mar; 56(3):289-95. PubMed ID: 12760685
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
